Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Raises Price Target to $67

RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and raises the price target from $64 to $67.
byBenzinga Newsdesk
July 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and raises the price target from $64 to $67.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More

By Jelena Martinovic
June 18, 12:48 AM
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics industries.Cybin Inc.announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development. In addition, six cannabis companies announced changes to their respective boards of directors.

CSE:PLTH